pubmed-article:9815805 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:9815805 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
pubmed-article:9815805 | lifeskim:mentions | umls-concept:C0005695 | lld:lifeskim |
pubmed-article:9815805 | lifeskim:mentions | umls-concept:C0025932 | lld:lifeskim |
pubmed-article:9815805 | lifeskim:mentions | umls-concept:C0522537 | lld:lifeskim |
pubmed-article:9815805 | lifeskim:mentions | umls-concept:C0067116 | lld:lifeskim |
pubmed-article:9815805 | pubmed:issue | 8 | lld:pubmed |
pubmed-article:9815805 | pubmed:dateCreated | 1999-2-25 | lld:pubmed |
pubmed-article:9815805 | pubmed:abstractText | The spermine analogue N1,N11-diethylnorspermine (DENSPM) has been shown to induce the polyamine-acetylating enzyme spermidine/spermine N1-acetyltransferase, disrupt polyamine pool homeostasis, and inhibit tumor growth. DENSPM is currently being developed as an anti-neoplastic agent and is about to enter Phase II clinical trials. In this report, the antitumor efficacy of DENSPM was evaluated against a human transitional cell bladder BL13 carcinoma xenograft implanted orthotopically and s.c. in nude athymic mice. DENSPM was administered via continuous s.c. infusion at 93 mg/kg/day for 5 days. Treatment with DENSPM was well tolerated and produced tumor regressions in all mice with a significant proportion (up to 50%) of apparent cures. On the basis of low toxicity and good therapeutic efficacy, there is a strong rationale for evaluation of the therapeutic efficacy of DENSPM against bladder carcinomas in Phase II clinical trials. | lld:pubmed |
pubmed-article:9815805 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9815805 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9815805 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9815805 | pubmed:language | eng | lld:pubmed |
pubmed-article:9815805 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9815805 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:9815805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9815805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9815805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9815805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9815805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9815805 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:9815805 | pubmed:month | Aug | lld:pubmed |
pubmed-article:9815805 | pubmed:issn | 1078-0432 | lld:pubmed |
pubmed-article:9815805 | pubmed:author | pubmed-author:BernackiR JRJ | lld:pubmed |
pubmed-article:9815805 | pubmed:author | pubmed-author:SharmaAA | lld:pubmed |
pubmed-article:9815805 | pubmed:author | pubmed-author:GlavesDD | lld:pubmed |
pubmed-article:9815805 | pubmed:author | pubmed-author:PorterC WCW | lld:pubmed |
pubmed-article:9815805 | pubmed:author | pubmed-author:RaghavanDD | lld:pubmed |
pubmed-article:9815805 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:9815805 | pubmed:volume | 3 | lld:pubmed |
pubmed-article:9815805 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:9815805 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:9815805 | pubmed:pagination | 1239-44 | lld:pubmed |
pubmed-article:9815805 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
pubmed-article:9815805 | pubmed:meshHeading | pubmed-meshheading:9815805-... | lld:pubmed |
pubmed-article:9815805 | pubmed:meshHeading | pubmed-meshheading:9815805-... | lld:pubmed |
pubmed-article:9815805 | pubmed:meshHeading | pubmed-meshheading:9815805-... | lld:pubmed |
pubmed-article:9815805 | pubmed:meshHeading | pubmed-meshheading:9815805-... | lld:pubmed |
pubmed-article:9815805 | pubmed:meshHeading | pubmed-meshheading:9815805-... | lld:pubmed |
pubmed-article:9815805 | pubmed:meshHeading | pubmed-meshheading:9815805-... | lld:pubmed |
pubmed-article:9815805 | pubmed:meshHeading | pubmed-meshheading:9815805-... | lld:pubmed |
pubmed-article:9815805 | pubmed:meshHeading | pubmed-meshheading:9815805-... | lld:pubmed |
pubmed-article:9815805 | pubmed:meshHeading | pubmed-meshheading:9815805-... | lld:pubmed |
pubmed-article:9815805 | pubmed:meshHeading | pubmed-meshheading:9815805-... | lld:pubmed |
pubmed-article:9815805 | pubmed:meshHeading | pubmed-meshheading:9815805-... | lld:pubmed |
pubmed-article:9815805 | pubmed:meshHeading | pubmed-meshheading:9815805-... | lld:pubmed |
pubmed-article:9815805 | pubmed:meshHeading | pubmed-meshheading:9815805-... | lld:pubmed |
pubmed-article:9815805 | pubmed:year | 1997 | lld:pubmed |
pubmed-article:9815805 | pubmed:articleTitle | Antitumor efficacy of N1,N11-diethylnorspermine on a human bladder tumor xenograft in nude athymic mice. | lld:pubmed |
pubmed-article:9815805 | pubmed:affiliation | Grace Cancer Drug Center and Division of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA. | lld:pubmed |
pubmed-article:9815805 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:9815805 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
pubmed-article:9815805 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9815805 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9815805 | lld:pubmed |